December 15, 2022
A day after hearing arguments from Mylan lawyers that AstraZeneca should be bound to a January 2023 expiration date of a patent protecting the blockbuster asthma treatment Symbicort, a federal judge in West Virginia ruled Thursday that AstraZeneca deserved at least six months more of market exclusivity.
July 12, 2022
A West Virginia federal judge on Tuesday refused to toss AstraZeneca's patent lawsuit against Mylan Pharmaceuticals and drug delivery service Kindeva, finding that AstraZeneca plausibly claims that the pair's recently FDA-approved generic version of its asthma treatment Symbicort infringes one of its drug patents.
April 26, 2022
After AstraZeneca obtained a drug patent related to asthma treatment Symbicort on Tuesday, the biopharmaceutical company wasted no time filing a patent suit the same day against Mylan and drug delivery service Kindeva in West Virginia federal court over an abbreviated new-drug application.